

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRSEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:30:58 ON 27 MAY 2008

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:31:09 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510542_specie2.str



chain nodes :

10 11 12 19 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18

chain bonds :

```

3-11  7-12  8-10  12-13  15-19  16-20  17-21
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  13-14  13-18  14-15  15-16  16-17
  17-18
exact/norm bonds :
5-7  6-9  7-8  8-9  8-10  16-20
exact bonds :
3-11  7-12  12-13  15-19  17-21
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-14  13-18  14-15  15-16  16-17  17-18

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:31:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:31:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> d l3 1-2

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN

RN 1015080-28-0 REGISTRY

ED Entered STN: 17 Apr 2008

CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydrochloride (1:2), mixt. with 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo-2H-indol-2-one (CA INDEX NAME)

FS STEREOSEARCH

MF C15 H24 N4 O6 . C15 H8 Br2 I N O2 . 2 Cl H

CI MXS

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 640725-71-9 (640281-90-9)

CMF C15 H24 N4 O6 . 2 Cl H

Absolute stereochemistry. Rotation (+).




● 2 HCl

CM 2

CRN 220904-83-6

CMF C15 H8 Br2 I N O2




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 220904-83-6 REGISTRY
ED Entered STN: 01 Apr 1999
CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)

OTHER NAMES:

CN 3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one
CN GW 5074
MF C15 H8 Br2 I N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, EMBASE, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

29 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
30 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	182.82	183.03

FILE 'REGISTRY' ENTERED AT 14:32:13 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1
DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> STR 220904-83-6

:END

L4 STRUCTURE CREATED

=> S L4 EXA FUL

FULL SEARCH INITIATED 14:32:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE


100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L5 1 SEA EXA FUL L4

=>

=> D SCAN

L5 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-
iodo-
MF C15 H8 Br2 I N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 220904-83-6 REGISTRY
ED Entered STN: 01 Apr 1999
CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-
iodo- (CA INDEX NAME)

OTHER NAMES:


CN 3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one

CN GW 5074

MF C15 H8 Br2 I N O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, EMBASE, PROUSDDR, SYNTHLINE,
TOXCENTER, USPAT2, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

29 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

30 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

62.31

245.34

FILE 'MEDLINE' ENTERED AT 14:32:40 ON 27 MAY 2008

FILE 'CAPLUS' ENTERED AT 14:32:40 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:32:40 ON 27 MAY 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 14:32:40 ON 27 MAY 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 15

SAMPLE SEARCH INITIATED 14:32:43 FILE 'WPIDS'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L6 37 L5

=> s 16 and (cancer? or tumor?)

L7 15 L6 AND (CANCER? OR TUMOR?)

=> s 17 and "breast cancer"

2 FILES SEARCHED...
L8 2 L7 AND "BREAST CANCER"

=> d l8 1-2 ibib, abs, hitstr

L8 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2006:228402 USPATFULL
TITLE: Small molecules that reduce fungal growth
INVENTOR(S): Johnson, Douglas I., Essex Junction, VT, UNITED STATES
Toenjes, Kurt A., Billings, MT, UNITED STATES
PATENT ASSIGNEE(S): University of Vermont and State Agricultural College,
Burlington, VT, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006194769	A1	20060831
APPLICATION INFO.:	US 2006-340418	A1	20060125 (11)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-646967P	20050125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1934	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to methods for reducing the growth of a fungus with an anti-fungal small molecule. Methods for reducing fungal cell growth in a subject with an anti-fungal small molecule and related compositions are provided. Topical lotion formulations of an anti-fungal small molecule and a topical carrier are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6 220904-83-6D, analogs
(small mols. that reduce fungal growth)
RN 220904-83-6 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



RN 220904-83-6 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L8 ANSWER 2 OF 2 USPATFULL on STN
 ACCESSION NUMBER: 2005:105536 USPATFULL
 TITLE: Methods and compositions for enhancing and inhibiting
 fertilization
 INVENTOR(S): Naor, Zvi, Tel Aviv, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090474	A1	20050428
APPLICATION INFO.:	US 2003-498830	A1	20030116 (10)
	WO 2003-IL44		20030116

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60348379	20020116
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Martin Moynihan, Anthony Castorina, 2001 Jefferson Davis Highway, Suite 207, Arlington, VA, 22202, US	
NUMBER OF CLAIMS:	122	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1880	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A method of contraception is provided. The method comprises providing to a subject an amount of a p38 activator and/or an ERK inhibitor capable of substantially reducing sperm motility. Also provided is a method of enhancing fertility comprising providing to a subject a therapeutically effective amount of a p38 inhibitor and/or an ERK activator, thereby enhancing fertility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6
 (as ERK inhibitor; methods and compns. for enhancing and inhibiting
 fertilization using a p38 activator/inhibitor and an ERK
 inhibitor/activator)

RN 220904-83-6 USPATFULL


CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-
 iodo- (CA INDEX NAME)



=> d 17 1-15 ibib ,abs, hitstr

L7 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:493012 CAPLUS
 TITLE: Compositions and methods for treating neurological disorders or damage
 INVENTOR(S): Diamandis, Phedias; Tyers, Mike; Dirks, Peter B.
 PATENT ASSIGNEE(S): Can.
 SOURCE: Can. Pat. Appl., 3pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CA 2606658	A1	20080413	CA 2007-2606658	20071012
PRIORITY APPLN. INFO.:				US 2006-851615P	P 20061013
AB	The invention relates to a clonogenic neurosphere assay to carry out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). The invention also relates to comps. comprising the identified modulators and methods of using the modulators and comps., in particular to treat neurol. disorders (e.g. brain or CNS cancer) or damage.				
IT	220904-83-6, GW5074 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (screening for comps. and methods for treating neurol. disorders or damage with modulators of neural stem cells)				
RN	220904-83-6 CAPLUS				
CN	2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)				



L7 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:352859 CAPLUS
 DOCUMENT NUMBER: 148:394354
 TITLE: Compositions and methods for treatment of viral diseases
 INVENTOR(S): Johansen, Lisa M.; Owens, Christopher M.; Mawhinney, Christina; Chappell, Todd W.; Brown, Alexander T.; Frank, Michael G.; Altmeyer, Ralf
 PATENT ASSIGNEE(S): Combinatorx (Singapore) Pre. Ltd., Singapore
 SOURCE: PCT Int. Appl., 237pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2008033466 A2 20080320 WO 2007-US19932 20070913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: US 2006-844463P P 20060914
US 2006-874061P P 20061211

AB Based on the results of the authors screen identifying compds. and combinations of compds. having antiviral activity, the present invention features compds., methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compds. that may be used to treat a viral disease.

IT 220904-83-6, GW 5074
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treatment of viral diseases)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L7 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2007:1333422 CAPLUS

DOCUMENT NUMBER: 147:528221

TITLE: Pharmaceutical synergistic combinations comprising an mTOR inhibitor and a Raf kinase inhibitor and its use in cancer treatment

INVENTOR(S): Lane, Heidi

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 56pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007131689	A2	20071122	WO 2007-EP4112	20070509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
 GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
 KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-9378 A 20060511
 OTHER SOURCE(S): MARPAT 147:528221

AB A pharmaceutical combination is disclosed comprising an mTOR inhibitor and
 a Raf kinase inhibitor as a synergistic drug combination, and its use in
 cancer treatment.
 IT 220904-83-6, GW5074
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical synergistic combinations comprising an mTOR inhibitor
 and a Raf kinase inhibitor and its use in cancer treatment)
 RN 220904-83-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-
 iodo- (CA INDEX NAME)



L7 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2007:506538 CAPLUS
 DOCUMENT NUMBER: 147:86651
 TITLE: Induction of differentiation of colon cancer
 cells by combined inhibition of kinases and histone
 deacetylase
 AUTHOR(S): Lea, Michael A.; Ibeh, Chinwe; Shah, Neel; Moyer, Mary
 P.
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology,
 UMDNJ - New Jersey Medical School, Newark, NJ, 07103,
 USA
 SOURCE: Anticancer Research (2007), 27(2), 741-748
 CODEN: ANTRD4; ISSN: 0250-7005
 PUBLISHER: International Institute of Anticancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The MAP kinase pathway inhibitor U0126 in combination with butyrate
 promotes differentiation in some colon cancer cell lines. We
 examined several inhibitors of histone deacetylase (HDAC) in combination
 with U0126 and other protein kinase inhibitors to see if these effects are
 general properties of HDAC inhibitors or butyrate alone. Alkaline phosphatase
 and peptidase activities were examined as markers for cellular
 differentiation in the human colon cancer cell lines Caco-2 and
 HT29 and the minimally transformed NCM460. Several HDAC inhibitors caused
 greater increases of alkaline phosphatase in the cancer cells than
 in NCM460, in which butyrate was the only HDAC inhibitor that caused a
 consistent increase. Unlike the JNK and PKC inhibitors examined, the MEK
 1/2 inhibitor U0126 induced alkaline phosphatase activity in Caco-2 as a


single agent and caused additive effects with HDAC inhibitors. The PI-3 kinase inhibitor LY294002 had little effect alone but enhanced the response of most HDAC inhibitors as did the raf inhibitor GW5074. In addition to butyrate, several HDAC inhibitors can induce differentiation in colon cancer cells and the responses may be enhanced by U0126, GW5074 and LY294002.

IT 220904-83-6, GW5074

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:87434 CAPLUS

DOCUMENT NUMBER: 146:182515

TITLE: Transgenic zebrafish model comprising Ras or other mammalian oncogene and its use in screening for antitumor agents or modulators of sensitivity to chemotherapy or radiation therapy

INVENTOR(S): Parinov, Sergey; Alexander, Emelyanov

PATENT ASSIGNEE(S): Temasek Life Sciences Laboratory Limited, Singapore

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007011312	A1	20070125	WO 2006-SG202	20060718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1906727	A1	20080409	EP 2006-769685	20060718
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2005-700310P	P 20050719

AB The present invention is directed to zebrafish tumorigenesis models, immortal tumor cell lines and to screening for anti-cancer agents. Transgenic zebrafish models are provided that contain Ras or other mammalian oncogenes operably linked to keratin 8 gene promoters and fused to enhanced green fluorescent protein. These zebrafish models may be utilized in methods of screening for drugs or agents that modulate oncogene-mediated neoplastic or hyperplastic transformation, or that modulate sensitivity to chemotherapy or radiation therapy. Immortal tumor cells lines, methods of making immortal tumor cell lines and methods of their use are also provided.

IT 220904-83-6, GW5074
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transgenic fish model comprising Ras or other mammalian oncogene and its use in screening for antitumor agents or modulators of sensitivity to chemotherapy or radiation therapy)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:845730 CAPLUS

DOCUMENT NUMBER: 145:278268

TITLE: Antitumor compositions containing antiangiogenic agents and aldesleukin for synergistic effect

INVENTOR(S): Aukerman, Sharon Lea; Denis-Mize, Kimberly; Elias, Laurence; Jallal, Bahija; Menezes, Daniel; Witherell, Gary W.

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 104pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006089150	A2	20060824	WO 2006-US5720	20060217
WO 2006089150	A3	20061102		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

AU 2006214138 A1 20060824 AU 2006-214138 20060217
CA 2598448 A1 20060824 CA 2006-2598448 20060217
EP 1853302 A2 20071114 EP 2006-735400 20060217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
MX 200710037 A 20080215 MX 2007-10037 20070817
IN 2007KN03324 A 20080321 IN 2007-KN3324 20070907
KR 2007108909 A 20071113 KR 2007-721118 20070914
CN 101146549 A 20080319 CN 2006-80009316 20070921
US 2005-654341P P 20050218
WO 2006-US5720 W 20060217

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 145:278268


AB The present invention relates to combination therapies with IL-2 compns. and antiangiogenic agents for the treatment of cancer. Further provided are methods of alleviating toxicities and increasing the efficacy associated with the administration of IL-2 compns. or antiangiogenic compns.

IT 220904-83-6P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (antitumor compns. containing antiangiogenic agents and aldesleukin for synergistic effect)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L7 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:239671 CAPLUS

DOCUMENT NUMBER: 144:425267

TITLE: Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells

AUTHOR(S): Edwards, Lincoln A.; Verreault, Maite; Thiessen, Brian; Dragowska, Wieslawa H.; Hu, Yanping; Yeung, Juliana H. F.; Dedhar, Shoukat; Bally, Marcel B.

CORPORATE SOURCE: Departments of Advanced Therapeutics, Medical Oncology, Cancer Genetics, BC Cancer Agency, University of British Columbia, Vancouver, BC, Can.

SOURCE: Molecular Cancer Therapeutics (2006), 5(3), 645-654
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The present study uses cell-based screening assays to assess the anticancer effects of targeting phosphatidylinositol 3-kinase-regulated integrin-linked kinase (ILK) in combination with small-mol. inhibitors of Raf-1 or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase (MEK). The objective was to determine if

synergistic interactions are achievable through the use of agents targeting two key cell signaling pathways involved in regulating glioblastoma cancer. The phosphatidylinositol 3-kinase/protein kinase B (PKB)/Akt and the Ras/MAPK pathway were targeted for their involvement in cell survival and cell proliferation, resp. The glioblastoma cell lines U87MG, SF-188, and U251MG were transiently transfected with an antisense oligonucleotide targeting ILK (ILKAS) alone or in combination with the Raf-1 inhibitor GW5074 or with the MEK inhibitor U0126. Dose and combination effects were analyzed by the Chou and Talalay median-effect method and indicated that combinations targeting ILK with either Raf-1 or MEK resulted in a synergistic interaction. Glioblastoma cells transfected with ILKAS exhibited reduced levels of ILK and phosphorylated PKB/Akt on Ser473 but not PKB/Akt on Thr308 as shown by immunoblot anal. These results were confirmed using glioblastoma cells transfected with ILK small interfering RNA, which also suggested enhanced gene silencing when used in combination with U0126. U87MG glioblastoma cells showed a 90% ($P < 0.05$) reduction in colony formation in soft agar with exposure to ILKAS in combination with GW5074 compared with control colonies. A substantial increase in Annexin V-pos. cells as determined by using fluorescence-activated cell sorting methods were seen in combinations that included ILKAS. Combinations targeting ILK and components of the Ras/MAPK pathway result in synergy and could potentially be more effective against glioblastoma cancer than monotherapy.


IT 220904-83-6, GW5074

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined inhibition of phosphatidylinositol 3-kinase/Akt and Ras/MAPK pathways results in synergistic effects in glioblastoma cells)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:570834 CAPLUS

DOCUMENT NUMBER: 139:128485

TITLE: Methods and compositions for enhancing and inhibiting fertilization using a p38 activator/inhibitor and an ERK inhibitor/activator

INVENTOR(S): Naor, Zvi

PATENT ASSIGNEE(S): Ramot at Tel Aviv University Ltd., Israel

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059373	A2	20030724	WO 2003-IL44	20030116

WO 2003059373 A3 20040129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003207961 A1 20030730 AU 2003-207961 20030116
 US 20050090474 A1 20050428 US 2004-498830 20040701

PRIORITY APPLN. INFO.: US 2002-348379P P 20020116
 WO 2003-IL44 W 20030116

AB A method of contraception is provided. The method comprises providing to a subject an amount of a p38 activator and/or an ERK inhibitor capable of substantially reducing sperm motility. Also provided is a method of enhancing fertility comprising providing to a subject a therapeutically effective amount of a p38 inhibitor and/or an ERK activator, thereby enhancing fertility. Articles-of-manufacture comprising a packaging material and a pharmaceutical composition identified as a contraceptive or fertility enhancer are also claimed. A method is also claimed of determining quality of

a semen sample, the method comprising determining p38 activity in sperm cells of the semen sample, said p38 activity being inversely indicative of sperm cell motility, thereby determining the quality of the semen sample. The method employs an antiphosphorylated p38 antibody or a kinase activity assay to determine p38 activity. A kit for determining quality of a semen sample, the


kit comprising a container including a reagent suitable for determining p38 activity in sperm cells of the semen sample is addnl. claimed.

IT 220904-83-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as ERK inhibitor; methods and compns. for enhancing and inhibiting fertilization using a p38 activator/inhibitor and an ERK inhibitor/activator)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L7 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:166598 CAPLUS

DOCUMENT NUMBER: 130:209599


TITLE: Preparation of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.

INVENTOR(S): McNutt, Robert Walton, Jr.; Jung, David Kendall; Harris, Philip Anthony; Hunter, Robert Neil, III; Veal, James Marvin; Dickerson, Scott; Lackey, Karen Elizabeth; Peel, Michael Robert

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910325	A1	19990304	WO 1998-EP4844	19980804
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9891584	A	19990316	AU 1998-91584	19980804
EP 1003721	A1	20000531	EP 1998-943832	19980804
EP 1003721	B1	20061102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2002514228	T	20020514	JP 1999-513839	19980804
IN 1998CA01381	A	20050311	IN 1998-CA1381	19980804
AT 344241	T	20061115	AT 1998-943832	19980804
ES 2272008	T3	20070416	ES 1998-943832	19980804
ZA 9807037	A	20000207	ZA 1998-7037	19980805
US 6268391	B1	20010731	US 2000-446586	20000407
PRIORITY APPLN. INFO.:			GB 1997-16557	A 19970806
			WO 1998-EP4844	W 19980804

OTHER SOURCE(S): MARPAT 130:209599
 GI



I

AB Title compds. [I; R1 = H; R1R2 = fused 5-10 membered aryl, heteroaryl, heterocyclyl; R2, R3 = H, HET, aryl, alipharyl, cyano, NO2, halo, R10, OR10, SR10, SOR10, SO2R10, NR10R11, etc.; R4 = H, halo, NO2, cyano; R5 = H, (substituted) alipharyl; R6, R7 = halo, cyano, NO2, CONR10R11, SO2NR10R11, NR10R11, OR11; R8 = OH, NHSO2R12, NHCOCF3; R10 = H, halo, (substituted) alipharyl, aryl, HET; R11 = H, R10; R12 = H, (substituted) alipharyl, HET; HET = benzofuryl, benzoxazolyl, dioxanyl, dithianyl, dithiazinyl, furyl, imidazolyl, indolyl, indazolyl, morpholinyl, tetrazolyl, pyrrolyl, quinolinyl, triazinyl, tetrahydrofuryl, etc.], were


prepared for treatment of tumor growth, preventing organ transplant rejection, healing chronic wounds, etc. (no data). Thus, 5-(2-methylthiazol-4-yl)-1,3-dihydroindol-2-one hydrochloride (preparation given) was stirred with 3,5-dibromo-4-hydroxybenzaldehyde in AcOH/aqueous HCl to give 64% 3-(3,5-dibromo-4-hydroxybenzylidene)-5-(2-methylthiazol-4-yl)-1,3-dihydroindol-2-one.

IT 220904-83-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.)

RN 220904-83-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 15 USPATFULL ON STN

ACCESSION NUMBER: 2006:228402 USPATFULL

TITLE: Small molecules that reduce fungal growth

INVENTOR(S): Johnson, Douglas I., Essex Junction, VT, UNITED STATES
Toenjes, Kurt A., Billings, MT, UNITED STATES

PATENT ASSIGNEE(S): University of Vermont and State Agricultural College,
Burlington, VT, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006194769	A1	20060831
APPLICATION INFO.:	US 2006-340418	A1	20060125 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-646967P	20050125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US	

NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 1934

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to methods for reducing the growth of a fungus with an anti-fungal small molecule. Methods for reducing fungal cell growth in a subject with an anti-fungal small molecule and related compositions are provided. Topical lotion formulations of an anti-fungal small molecule and a topical carrier are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6 220904-83-6D, analogs
(small mols. that reduce fungal growth)


RN 220904-83-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



RN 220904-83-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L7 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:287571 USPATFULL

TITLE: Use of C-Raf inhibitors for the treatment of neurodegenerative diseases

INVENTOR(S): D'Mello, Santosh R., Dallas, TX, UNITED STATES
Chin, Paul C., Plano, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005250837	A1	20051110
APPLICATION INFO.:	US 2003-688759	A1	20031017 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-419439P	20021018 (60)
	US 2003-440177P	20030115 (60)

DOCUMENT TYPE:

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Scott C. Sample, Locke Liddell & Sapp LLP, 2200 Ross Avenue, Suite 2200, Dallas, TX, 75201-6776, US

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)


LINE COUNT: 1561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB C-Raf inhibitors, especially oxindole derivatives such as 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone, are used for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury. C-Raf inhibitors are included in the manufacture of compositions for the treatment of neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6, GW 5074
 (C-raf inhibitors for treatment of neurodegenerative diseases)
 RN 220904-83-6 USPATFULL
 CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-
 iodo- (CA INDEX NAME)



L7 ANSWER 12 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2005:183990 USPATFULL
 TITLE: JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV
 infection
 INVENTOR(S): Mohapatra, Shyam S., Tampa, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005159385	A1	20050721
APPLICATION INFO.:	US 2004-18954	A1	20041220 (11)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531052P	20031219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	2773	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6, GW5074
 (JAK/STAT inhibitors and MAPK/ERK inhibitors for respiratory syncytial
 virus infection treatment)
 RN 220904-83-6 USPATFULL
 CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-
 iodo- (CA INDEX NAME)



L7 ANSWER 13 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2005:105536 USPATFULL
 TITLE: Methods and compositions for enhancing and inhibiting fertilization
 INVENTOR(S): Naor, Zvi, Tel Aviv, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090474	A1	20050428
APPLICATION INFO.:	US 2003-498830	A1	20030116 (10)
	WO 2003-IL44		20030116

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60348379	20020116
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Martin Moynihan, Anthony Castorina, 2001 Jefferson Davis Highway, Suite 207, Arlington, VA, 22202, US	

NUMBER OF CLAIMS: 122
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Page(s)
 LINE COUNT: 1880

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A method of contraception is provided. The method comprises providing to a subject an amount of a p38 activator and/or an ERK inhibitor capable of substantially reducing sperm motility. Also provided is a method of enhancing fertility comprising providing to a subject a therapeutically effective amount of a p38 inhibitor and/or an ERK activator, thereby enhancing fertility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6
 (as ERK inhibitor; methods and compns. for enhancing and inhibiting fertilization using a p38 activator/inhibitor and an ERK inhibitor/activator)

RN 220904-83-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L7 ANSWER 14 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2004:57386 USPATFULL
 TITLE: Three hybrid assay system

INVENTOR(S): Come, Jon H., Cambridge, MA, UNITED STATES
 Becker, Frank, Planegg, GERMANY, FEDERAL REPUBLIC OF
 Kley, Nikolai A., Wellesley, MA, UNITED STATES
 Reichel, Christoph, Planegg, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043388	A1	20040304
	US 7135550	B2	20061114
APPLICATION INFO.:	US 2002-234985	A1	20020903 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-91177, filed on 4 Mar 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-272932P	20010302 (60)
	US 2001-278233P	20010323 (60)
	US 2001-329437P	20011015 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624

NUMBER OF CLAIMS: 96
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 18 Drawing Page(s)
 LINE COUNT: 8493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6D, conjugates
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 220904-83-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



L7 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:121498 USPATFULL

TITLE: Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases

INVENTOR(S): Dickerson, Scott Howard, Chapel Hill, NC, United States
 Harris, Philip Anthony, Raleigh, NC, United States
 Hunter, III, Robert Neil, Raleigh, NC, United States
 Jung, David Kendall, Durham, NC, United States
 Lackey, Karen Elizabeth, Hillsborough, NC, United States

PATENT ASSIGNEE(S):

McNutt, Jr., Robert Walton, Durham, NC, United States
 Peel, Michael Robert, Chapel Hill, NC, United States
 Veal, James Marvin, Apex, NC, United States
 Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268391	B1	20010731
	WO 9910325		19990304
APPLICATION INFO.:	US 2000-446586		20000407 (9)
	WO 1998-EP4844		19980804
			20000407 PCT 371 date
			20000407 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-16557	19970806
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Aulakh, C. S.	
LEGAL REPRESENTATIVE:	Lemanowicz, John L.	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3662	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of general formula (I) wherein: R.sup.1 is H or optionally joined with R.sup.2 to form a fused ring selected from the group consisting of five to ten membered aryl, heteroaryl or heterocyclyl rings, R.sup.2 and R.sup.3 are independently H, HET, aryl, C.sub.1-12 aliphatic, CN, NO.sub.2, halogen, R.sup.10, --OR.sup.10, --SR.sup.10, --S(O)R.sup.10, --SO.sub.2 R.sup.10, --NR.sup.10 R.sup.11, --NR.sup.11 R.sup.12, --NR.sup.12 COR.sup.11, --NR.sup.12 CO.sub.2 R.sup.11, --NR.sup.12 CONR.sup.11 R.sup.12, --NO.sub.2 SO.sub.2 R.sup.11, --NR.sup.12 C(NR .sup.12)NHR.sup.11, --COR.sup.11, --CO.sub.2 R.sup.11, --CONR.sup.12 R.sup.11, --SO.sub.2 NR.sup.12 R.sup.11, --OCONR.sup.12 R.sup.11, C(NR.sup.12)NR.sup.12 R.sup.11, R.sup.6 and R.sup.7 are independently halogen, CN, NO.sub.2, --CONR.sup.10 R.sup.11, --SO.sub.2 NR.sup.10 R.sup.11, --NR.sup.10 R.sup.11, or --OR.sup.11, where R.sup.10 and R.sup.11 are as defined below; R.sup.8 is OH, NHSO.sub.2 R.sup.12 or NHCOCF.sub.3; and their use in therapy, especially in the treatment of disorders mediated by cRaf1 kinase.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220904-83-6P

(preparation of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.)

RN 220904-83-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo- (CA INDEX NAME)



=>
Connection closed by remote host
d his

---Logging off of STN---

END

Unable to generate the STN prompt.
Exiting the script...